Samuel So, MD
General Surgery · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 13
- 2 carriers
- Office
- 1
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
13 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. So’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
13 of 13 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence A51497 · Current
Licensed to practise in California · since 1992 · expires 2028-07-31 · University of Hong Kong Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$2,031
Medicare paid this office $2,031 for 16 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Short return visit (20+ min) | 16 | $1,975 | $82 |
Who their Medicare patients are
16 Original Medicare patients in 2024. Average age 77 · Under 65 0% · Health risk score 1.53. At or below the middle of the specialty; the typical general surgery clinician is at 1.69.
Conditions among them: High blood pressure 69%.
The office billed $16,077, Medicare allowed $2,729 and paid $2,031; for 25 services of 2 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 16 | 25 | 77 | 1.53 | $16,077 | $2,031 |
| 2023 | 15 | 27 | 77 | 1.48 | $15,017 | $1,281 |
| 2022 | 19 | 30 | 75 | 1.16 | $15,987 | $1,439 |
| 2021 | 21 | 33 | 75 | 1.42 | $18,587 | $2,003 |
| 2020 | 24 | 35 | 74 | 1.91 | $12,707 | $1,561 |
| 2019 | 28 | 45 | 75 | 1.72 | $4,711 | $2,010 |
| 2018 | 28 | 56 | 76 | 1.84 | $3,567 | $2,252 |
| 2017 | 36 | 66 | 77 | 1.92 | $6,051 | $2,732 |
| 2016 | 36 | 63 | 77 | 1.93 | $6,845 | $2,390 |
| 2015 | 42 | 79 | 76 | 1.69 | $10,370 | $3,615 |
| 2014 | 52 | 98 | 76 | 1.83 | $21,213 | $6,653 |
| 2013 | 53 | 100 | 75 | 1.91 | $21,699 | $5,443 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 1 service
| Short return visit (20+ min) | 15 | $1,281 | $49 |
2022: 1 service
| Short return visit (20+ min) | 18 | $1,189 | $48 |
2021: 1 service
| Short return visit (20+ min) | 15 | $1,319 | $53 |
2020: 1 service
| Short return visit (20+ min) | 19 | $832 | $31 |
2019: 1 service
| Short return visit (20+ min) | 25 | $1,718 | $42 |
2018: 1 service
| Short return visit (20+ min) | 27 | $2,163 | $39 |
2017: 1 service
| Short return visit (20+ min) | 33 | $2,378 | $41 |
2016: 1 service
| Short return visit (20+ min) | 34 | $2,084 | $37 |
2015: 1 service
| Short return visit (20+ min) | 39 | $2,953 | $41 |
2014: 1 service
| Short return visit (20+ min) | 43 | $3,412 | $41 |
2013: 1 service
| Short return visit (20+ min) | 49 | $3,209 | $36 |
Drugs they prescribed that Part D paid
$41,619
Pharmacies billed $41,619 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 72) in 2024. At or below the middle of the specialty; the typical general surgery clinician is at 34%.
43 generic and 29 brand-name prescriptions · $41,619 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Vemlidy | 23 | $31,710 | $1,379 |
| Entecavir | 29 | $1,451 | $50 |
Year by year
| 2024 | 72 | 14 | 0% (0) | 40% | $41,619 |
| 2023 | 66 | 13 | 0% (0) | 47% | $48,234 |
| 2022 | 88 | 17 | 0% (0) | None | $49,836 |
| 2021 | 95 | 17 | 0% (0) | 32% | $54,148 |
| 2020 | 94 | 16 | 0% (0) | 17% | $42,336 |
| 2019 | 141 | 17 | 0% (0) | 12% | $45,522 |
| 2018 | 163 | 21 | 0% (0) | 23% | $100,362 |
| 2017 | 172 | 22 | 0% (0) | 65% | $320,637 |
| 2016 | 137 | 19 | 0% (0) | 72% | $179,916 |
| 2015 | 164 | 23 | 0% (0) | 76% | $170,929 |
| 2014 | 204 | 27 | 0% (0) | 68% | $209,085 |
| 2013 | 166 | 27 | None | 89% | $147,769 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 2 drugs
| Vemlidy | 27 | $40,080 | $1,484 |
| Entecavir | 23 | $6,234 | $271 |
2022: 3 drugs
| Vemlidy | 24 | $33,642 | $1,402 |
| Tenofovir Disoproxil | 24 | $10,194 | $425 |
| Entecavir | 32 | $5,854 | $183 |
2021: 3 drugs
| Vemlidy | 26 | $33,790 | $1,300 |
| Entecavir | 28 | $5,561 | $199 |
| Tenofovir Disoproxil | 24 | $4,079 | $170 |
2020: 3 drugs
| Vemlidy | 16 | $19,415 | $1,213 |
| Tenofovir Disoproxil | 40 | $13,219 | $330 |
| Entecavir | 30 | $8,259 | $275 |
2019: 3 drugs
| Vemlidy | 16 | $17,991 | $1,124 |
| Tenofovir Disoproxil | 78 | $12,706 | $163 |
| Entecavir | 40 | $11,940 | $298 |
2018: 3 drugs
| Tenofovir Disoproxil | 69 | $27,662 | $401 |
| Entecavir | 38 | $20,101 | $529 |
| Viread | 16 | $18,375 | $1,148 |
2017: 2 drugs
| Viread | 98 | $108,172 | $1,104 |
| Entecavir | 48 | $37,867 | $789 |
2016: 3 drugs
| Viread | 76 | $80,939 | $1,065 |
| Entecavir | 34 | $32,769 | $964 |
| Baraclude | 15 | $19,913 | $1,328 |
2015: 4 drugs
| Viread | 83 | $94,524 | $1,139 |
| Baraclude | 32 | $40,488 | $1,265 |
| Entecavir | 17 | $23,012 | $1,354 |
| Lamivudine Hbv | 11 | $9,247 | $841 |
2014: 5 drugs
| Viread | 67 | $78,743 | $1,175 |
| Baraclude | 39 | $64,036 | $1,642 |
| Adefovir Dipivoxil | 25 | $22,602 | $904 |
| Lamivudine Hbv | 22 | $16,007 | $728 |
| Epivir Hbv | 23 | $12,313 | $535 |
2013: 4 drugs
| Viread | 50 | $45,689 | $914 |
| Baraclude | 19 | $33,092 | $1,742 |
| Epivir Hbv | 40 | $28,313 | $708 |
| Hepsera | 25 | $26,611 | $1,064 |
Money from drug and device companies
$16 in 2025
A payment is not proof that care is biased.
| GlaxoSmithKline | None | $16 | 1 payment
|
See the published payment
| GlaxoSmithKline | Meals · 2025-11-08 | None | $16 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1982730065
- Licence
- CA A51497California A51497: Current · expires 2028-07-31
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00A514970
- Taxonomy
- Surgery (208600000X); Surgical oncology (2086X0206X)
- Mailing address
- 300 Pasteur Dr, Palo Alto, CA, 94305
- NPI first listed
- 2007-02-26
- NPI last updated
- 2024-04-27
- NPI record certified
- 2024-04-27
This is when the NPI record was last certified, not a medical board exam.